PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer

BACKGROUND: In patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), immune checkpoint blockade is ineffective, and combinatorial approaches enhancing immunogenicity need exploration. METHODS: We treated 43 patients with predominantly microsatellite stable RAS/BRAF wild-type...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Alexander, Simnica, Donjete, Schultheiß, Christoph, Scholz, Rebekka, Tintelnot, Joseph, Gökkurt, Eray, von Wenserski, Lisa, Willscher, Edith, Paschold, Lisa, Sauer, Markus, Lorenzen, Sylvie, Riera-Knorrenschild, Jorge, Depenbusch, Reinhard, Ettrich, Thomas J, Dörfel, Steffen, Al-Batran, Salah-Eddin, Karthaus, Meinolf, Pelzer, Uwe, Waberer, Lisa, Hinke, Axel, Bauer, Marcus, Massa, Chiara, Seliger, Barbara, Wickenhauser, Claudia, Bokemeyer, Carsten, Hegewisch-Becker, Susanna, Binder, Mascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317124/
https://www.ncbi.nlm.nih.gov/pubmed/34315821
http://dx.doi.org/10.1136/jitc-2021-002844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317124/
https://www.ncbi.nlm.nih.gov/pubmed/34315821
http://dx.doi.org/10.1136/jitc-2021-002844

Ejemplares similares